GLPwatch
Papers (12034)
Page 107 of 201, ranked by citation count.
- Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study.
- Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4.
- Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients.
- Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report.
- Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome.
- Optimizing management of glycaemia.
- Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
- Semaglutide Aggregates into Oligomeric Micelles and Short Fibrils in Aqueous Solution.
- Emerging Role of Semaglutide and GLP-1 Agonist Medications in Plastic Surgery: A Note of Caution.
- Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design.
- Semaglutide-induced Hyperemesis Gravidarum.
- Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery.
- Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials.
- IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study.
- Liraglutide Treatment in a Morbidly Obese Adolescent with a <i>MC4R</i> Gene Variant: Side Effects Reduce Success
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved ejection fraction: decongestion or disease modification?
- Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.
- Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
- Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
- Non-Arteritic Anterior Ischemic Optic Neuropathy in an Otherwise Healthy Young Adult Patient Treated with Liraglutide and Semaglutide for Weight Loss: A Cautionary Tale.
- Incretin receptor agonism during pregnancy: implications for mother and baby.
- Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation.
- Exploring Liraglutide in Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy Model in Rats: Impact on Inflammation, Mitochondrial Function, and Behavior.
- Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.
- [Exenatide stimulated solute-free water excretion by human kidney].
- Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.
- SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
- Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months.
- Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.
- Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.
- [Liraglutide promotes proliferation and migration of cardiac microvascular endothelial cells through PI3K/Akt and MAPK/ERK signaling pathways].
- [Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease].
- Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
- Neuroprotective effects of semaglutide and metformin against rotenone-induced neurobehavioral changes in male diabetic rats.
- Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.
- Explore the Effect and Target of Liraglutide on Islet Function in Type 2 Diabetic Rats by miRNA Omics Technology.
- Structure-Activity Relationships and Pharmacokinetics of <sup>111</sup>In-Labeled Glucagon-like Peptide-1 Receptor-Targeting Exendin-4 Derivatives Conjugated with Albumin Binder Moieties.
- Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch<sup>®</sup> among self-injection-naïve patients with type 2 diabetes mellitus in Japan.
- Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats.
- Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
- Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline.
- Tirzepatide Improves Early Dumping Syndrome and Glucose Nadir in Postbariatric Hypoglycemia After Sleeve Gastrectomy.
- Efficacy and Safety of a Biosimilar Liraglutide (Melitide<sup>®</sup>) Versus the Reference Liraglutide (Victoza<sup>®</sup>) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial.
- The importance of patient-reported outcomes in type 2 diabetes: insight from the PIONEER program with oral semaglutide.
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.
- Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials.
- Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series.
- Turning fat into muscle: can this be an alternative to anti-obesity drugs such as semaglutide?
- Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
- Lipidized Prolactin-Releasing Peptide Agonist Attenuates Hypothermia-Induced Tau Hyperphosphorylation in Neurons.
- Preparation and characterization of BSA-loaded liraglutide and platelet fragment nanoparticle delivery system for the treatment of diabetic atherosclerosis.
- Expectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes - Case Presentations.
- Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
- Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.
- Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect.
- Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.
- SAD-A Promotes Glucose-Stimulated Insulin Secretion Through Phosphorylation and Inhibition of GDIα in Male Islet β Cells.
- Pseudo-Wang Handle for the Preparation of Fully Protected Peptides. Synthesis of Liraglutide by Fragment Condensation.
- Anti-diabetic properties of a non-conventional radical scavenger, as compared to pioglitazone and exendin-4, in streptozotocin-nicotinamide diabetic mice.